Artisan Partners Limited Partnership Sells 163,266 Shares of argenex SE $ARGX

Artisan Partners Limited Partnership trimmed its position in shares of argenex SE (NASDAQ:ARGX) by 6.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,186,510 shares of the company’s stock after selling 163,266 shares during the quarter. argenex makes up about 2.3% of Artisan Partners Limited Partnership’s investment portfolio, making the stock its 6th largest holding. Artisan Partners Limited Partnership owned approximately 3.55% of argenex worth $1,612,682,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. AQR Capital Management LLC boosted its holdings in argenex by 32.1% in the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock worth $297,000 after purchasing an additional 122 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of argenex by 5,962.5% in the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after buying an additional 1,431 shares during the last quarter. Focus Partners Wealth boosted its stake in shares of argenex by 22.3% during the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after acquiring an additional 73 shares in the last quarter. Geneos Wealth Management Inc. boosted its stake in shares of argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after acquiring an additional 99 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of argenex by 27.1% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,934 shares of the company’s stock valued at $1,066,000 after acquiring an additional 412 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenex Stock Performance

NASDAQ:ARGX opened at $771.53 on Friday. The company has a market cap of $47.74 billion, a P/E ratio of 33.13, a P/E/G ratio of 0.71 and a beta of 0.37. argenex SE has a 52-week low of $510.05 and a 52-week high of $934.62. The stock’s 50-day simple moving average is $828.13 and its 200 day simple moving average is $809.87.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.05 by $1.97. The firm had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.30 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. As a group, equities analysts predict that argenex SE will post 3.13 earnings per share for the current fiscal year.

Trending Headlines about argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx reported strong Q4 and full‑year 2025 financials: Q4 revenue of $1.32B and FY product net sales of $4.2B (≈90% YoY growth); Q4 EPS of $8.02 beat consensus. These results support the company’s near‑term commercial momentum. Read More.
• Positive Sentiment: argenx announced positive topline Phase 3 ADAPT OCULUS results for VYVGART in ocular myasthenia gravis (met primary endpoint, p=0.012). Management plans an sBLA to expand the U.S. label — a potential near‑term regulatory catalyst and incremental sales opportunity. Read More.
• Neutral Sentiment: Management hosted a Q4 earnings release and posted supporting materials (slide deck, call transcript) — useful for investors seeking detailed guidance, uptake trends, and commercial assumptions. Read More.
• Neutral Sentiment: Analyst previews and earnings commentary were published ahead/around the print, offering perspectives on forecast revisions and expectations. These pieces summarize consensus and may influence short‑term analyst moves. Read More. · Read More.
• Neutral Sentiment: Reported short‑interest data for February appears anomalous (entries show zero shares/NaN changes and a 0.0 days‑to‑cover); treat these data points cautiously — they likely reflect a reporting glitch rather than a substantive change in short positioning.
• Negative Sentiment: Despite the positive news, shares are lower on heavy volume — likely driven by profit‑taking after a strong run and valuation considerations (PE ~33). Elevated intraday turnover can amplify price moves even after beats. Read More.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Truist Financial raised their target price on shares of argenex from $950.00 to $1,030.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Stifel Nicolaus upped their target price on shares of argenex from $1,028.00 to $1,248.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. DZ Bank raised argenex to a “strong-buy” rating in a report on Friday, December 19th. Royal Bank Of Canada raised their price target on argenex from $860.00 to $925.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Finally, Robert W. Baird downgraded argenex from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $986.78.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.